Bristol Myers Squibb Company reported $11.6bn in third quarter revenue that exceeded analyst consensus on 27 October, driven in part by newer product sales, which more than doubled from Q1 to Q3. The company, under pressure to produce significant revenue growth before mega-blockbuster Revlimid (lenalidomide) begins to face loss of exclusivity next year, also largely has seen success in its research and development pipeline since acquiring Celgene Corporation at the end of 2019 despite some initial stumbles.
Volume-limited Revlimid generics will begin to launch in the US in 2022 along with generics in some ex-US markets. The...
